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Degenerative cervical myelopathy (DCM) is an overarching term used to describe an array of degenerative changes that narrow the spinal canal and compress the spinal cord.^[@bib1]^ Patients with DCM usually present with at least one of the following symptoms: weakness and/or numbness of the upper limbs, reduced manual dexterity, unstable gait, neuropathic pain, and bladder dysfunction. In addition, they can present with at least one of the following neurological signs: hyperreflexia, positive Hoffman\'s sign, positive plantar response, long tract signs, intrinsic hand muscle weakness, and lower limb spasticity. Functional impairment in these patients can significantly reduce independence and quality of life.^[@bib3]^ Recent guidelines have recommended surgical decompression as the preferred treatment strategy for patients with moderate to severe DCM.^[@bib7]^ Patients with mild myelopathy, however, may benefit from a trial of non-operative intervention provided their disease is stable.^[@bib10]^

Cardinal symptoms of DCM include impaired manual dexterity and weakness of the intrinsic hand muscles.^[@bib4],[@bib8]^ As such, characterizing hand function is essential for understanding the natural history of the disease and defining optimal management strategies, especially in patients with mild DCM. Several studies have indicated that the refined components of hand function are not always responsive to decompressive surgery and that manual dexterity may not completely recover to baseline following treatment.^[@bib14]^ Dexterity is a complex function that is difficult to objectively quantify. Although the modified Japanese Orthopaedic Association (mJOA) score includes an upper limb motor and sensory subscore, it is a coarse self-reported measure that does not fully define a patient\'s functional impairment or hand deficits.^[@bib17]^

A barrier in defining DCM management is the lack of an assessment tool that can characterize the motor, sensory, and dexterity changes that occur in the hand following cord compression. To fill this critical knowledge gap, we conducted an observational cross-sectional study to characterize upper limb function and hand impairment in patients with mild, moderate, and severe DCM, and develop and validate a sensitive and specific assessment tool to better quantify upper limb impairment in these patients. The sensitivity and psychometric properties of the Graded Redefined Assessment of Strength, Sensibility, and Prehension -- Version Myelopathy (GRASSP-M) were assessed.

METHODS {#sec2}
=======

Study Design {#sec2-1}
------------

A single-center, observational, cross-sectional study was conducted at Toronto Western Hospital between May 2013 and December 2016. Research ethics board approval was obtained and informed consent was provided by participating patients.

Patients were enrolled in this study if they satisfied the following criteria: 1 or more signs of myelopathy (corticospinal motor deficits, hand atrophy, hyperreflexia, a positive Hoffman sign, upgoing plantar reflexes, lower limb spasticity, and/or gait ataxia); 1 or more symptoms of myelopathy (numb hands, clumsy hands, gait impairment, bilateral hand paresthesia, L'Hermitte\'s phenomena, and/or weakness); and evidence of compression of the spinal cord on magnetic resonance imaging (MRI). Patients were excluded if their upper limb deficit could not be entirely explained by cervical cord compression (focal neurological comorbidities such as stroke, multiple sclerosis, rheumatoid arthritis, brachial plexus injury, and peripheral neuropathies); they were unable to speak English; or they were medically unstable. Furthermore, individuals with a diagnosis of diabetes and no clinical evidence of neuropathy were included as well as individuals with hypertension. Healthy controls were recruited through the clinical research team\'s networks, patients who presented to the spine program with no cervical or upper limb deficits, and clinicians at the hospital that were above the age of 45. There was an emphasis on recruiting control subjects that would serve as an age-matched control group.

Severity of functional impairment was classified using the mJOA scale. Patients were stratified into mild (mJOA = 15-17), moderate (mJOA = 12-14), and severe (mJOA \< 12) groups.^[@bib10],[@bib11]^ Data were collected from each patient, including demographic information, findings from a neurological exam, mJOA, QuickDASH, grip dynamometry, and GRASSP-M scores. Grip strength was measured 3 times and results were averaged across trials. Videotaped GRASSP-M prehension/dexterity tasks were reviewed and independently scored by 2 assessors (blinded to DCM severity), and inter-rater reliability was computed (n = 44). A subset of patients were asked to perform the prehension/dexterity task 2 times in 1 day; a single assessor scored both performances, and intra-rater reliability data were evaluated (n = 31). Reliability of the strength and sensation subtests was previously assessed.^[@bib18]^

Scales/Outcomes {#sec2-2}
---------------

The mJOA scale consists of 4 categories: motor dysfunction of the upper limbs (5 points) and lower limbs (7 points), sensory impairment of the upper limbs (3 points), and bladder dysfunction (3 points). A score of 18 represents no functional deficit. The QuickDASH is a measure of self-perceived disability (patient reported outcome), which evaluates symptoms associated with upper limb, neck, and musculoskeletal disorders; the higher the score, the greater the disability.^[@bib19]^ Grip dynamometry measures handgrip force; greater force equates to greater strength.^[@bib20],[@bib21]^ GRASSP-M evaluates hand impairment through strength, sensation, and prehension/dexterity subtests; scores closer to zero demonstrate greater deficit.

Modifications to the GRASSP Version 1.0 {#sec2-3}
---------------------------------------

The GRASSP Version 1.0 (GRASSP-V1; Neural Outcomes, Toronto, Canada) is a reliable and valid outcome measure originally developed to measure upper limb impairment in patients with traumatic tetraplegia. This tool is sensitive in detecting the sensory, motor, and functional changes that occur within 1 yr following injury^[@bib18],[@bib22]^; however, it is not sensitive enough to capture the upper limb deficits in DCM patients. As a result, the following modifications were made to the GRASSP-V1 to increase its applicability in patients with DCM (Figure [1](#fig1){ref-type="fig"}): Sensation: Measurement of upper limb sensation was reduced from palmar and dorsal sensation to palmar sensation only.Prehension: The GRASSP-M was developed to specifically analyze manual dexterity. The prehension portion of GRASSP-V1 consists of 6 prehension tasks scored on a 5-point scale; this section was reduced to a single task and the scoring was modified to objectively define dexterous function. These changes give the scale greater sensitivity to better discriminate dexterity differences among patients with mild, moderate, and severe DCM.Strength testing was not modified.

![Development of the GRASSP-M. This figure defines the domains in the original GRASSP and the reduced domains in the GRASSP-myelopathy.](nyz499fig1){#fig1}

Analysis {#sec2-4}
--------

Statistical analysis was performed using SPSS Version 21.0 (IBM, Armonk, New York). Continuous variables were described using means and standard deviations, and categorical variables were summarized using frequencies. The significance level was set at *P* ≤ .05. Differences in manual dexterity scores between the dominant and non-dominant hand were evaluated using paired *t*-tests. Differences in age and gender distribution between healthy controls and DCM patients were assessed using an unpaired 2-way *t*-test (unequal variance) and chi square test, respectively. Analysis of variance and/or unpaired 2-way *t*-tests (unequal variance) were used to evaluate differences in strength, sensation, and dexterity between controls and DCM patients, as well as among patients with mild, moderate, and severe myelopathy.

Inter- and intra-rater reliabilities were calculated using intraclass correlation coefficient (ICC) under the 2-way random effects model; an ICC of 0.75 was considered acceptable.^[@bib23]^

To assess concurrent validity, the following hypothesis was first generated: the GRASSP-M can discriminate among patients with mild, moderate, and severe myelopathy but does not perfectly correlate with the mJOA. Pearson correlation coefficients were computed to evaluate the association between the GRASSP-M strength, sensation, and prehension/dexterity subtests and the subscores of the mJOA that measure upper limb function. A moderate, positive correlation would demonstrate concurrent validity. Known-groups validity was used to establish construct validity. Unpaired 2-way *t*-tests (unequal variance) with a Bonferroni correction (*P* ≤ .016) were used to examine whether patients with mild, moderate, and severe DCM (based on the mJOA) could be differentiated by their GRASSP-M strength, sensation, and prehension/dexterity subtest scores.

RESULTS {#sec3}
=======

Sample {#sec3-1}
------

A total of 148 study participants and 21 control subjects were enrolled. The sample consisted of 84 males and 64 females, with a mean age of 56.89 ± 10.67 yr. Mean duration of symptoms was 45.5 ± 60.4 mo. The control sample consisted of 11 males and 10 females, with a mean age of 53.67 ± 16.81 yr. No significant differences in the age (*P* = .403) and gender (*P* = .705) distribution between healthy controls and DCM patients were present. The sample consisted of 75 mild (mJOA 15.85 ± 0.748), 41 moderate (mJOA 13.20 ± 0.782), and 32 severe (mJOA 9.94 ± 1.110) patients.

Scores {#sec3-2}
------

Table [1](#tbl1){ref-type="table"} reports baseline mJOA, QuickDASH, grip strength, and GRASSP-M subtest (strength, sensation, and prehension/dexterity) scores for DCM patients and controls. Figure [2](#fig2){ref-type="fig"} illustrates the dexterity scores of patients with DCM and controls. GRASSP-M strength scores in the dominant hand were weaker in patients with moderate (vs mild) and severe (vs mild and moderate) myelopathy. GRASSP-M sensation scores were also reduced in patients with severe myelopathy compared to those with mild and moderate myelopathy in both the dominant and non-dominant hand. GRASSP-M sensation scores, however, were not significantly different between patients with mild and moderate DCM. Finally, GRASSP-M prehension/dexterity scores were different between controls and patients with DCM, as well as among patients with mild, moderate, and severe myelopathy in both the dominant and non-dominant hands. The mean values in Table [1](#tbl1){ref-type="table"} were used to set GRASSP-M severity thresholds.

![Dexterity scores for healthy controls and patients. This figure demonstrates the discrimination of severity of DCM compared with healthy controls. The dexterity score defines even the subtle deficit in the mild DCM patient.](nyz499fig2){#fig2}

###### 

Sample Data Stratified by mJOA

  Variable                        Control (n = 21) mean (SD)   Mild (n = 75) mean (SD)                                                                                                 Moderate (n = 41) mean (SD)                                                                                             Severe (n = 32) mean (SD)                                                                                               
  ------------------------------- ---------------------------- ----------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------
  Duration of symptoms (months)   0                            40.16 (±58.25)                                                                                                          57.62 (±63.36)                                                                                                          41.46 (±61.01)                                                                                                          
  mJOA (/18)                      18                           15.85 (±0.748)                                                                                                          13.20 (±0.782)                                                                                                          9.94 (±1.11)                                                                                                            
  UL mJOA (/8)                    8                            6.43 (±0.701)                                                                                                           5.29 (±0.901)                                                                                                           4.19 (±0.780)                                                                                                           
  UL motor mJOA (/5)              5                            4.47 (±0.502)                                                                                                           3.59 (±0.631)                                                                                                           2.81 (±0.738)                                                                                                           
  Sensation mJOA (/3)             3                            1.96 (±0.478)                                                                                                           1.71 (±0.512)                                                                                                           1.38 (±0.554)                                                                                                           
  QuickDASH (%)                   0                            27.59 (±17.26)                                                                                                          45.07 (±19.83)                                                                                                          62.12 (±22.41)                                                                                                          
  Grip strength                   Dominant (Kg)                35.92[^†^](#tb1fn7){ref-type="table-fn"}                                                                                31.00 (±13.34)                                                                                                          27.05 (±19.83)                                                                                                          24.92 (±9.71)
                                  Non-dominant (Kg)            29.60[^†^](#tb1fn7){ref-type="table-fn"}                                                                                30.25 (±12.60)                                                                                                          26.13 (±13.24)                                                                                                          24.38 (±9.05)
  GRASSP-M strength               Dominant (/50)               50[^‡^](#tb1fn8){ref-type="table-fn"}                                                                                   47.95^[a](#tb1fn1){ref-type="table-fn"},[c](#tb1fn3){ref-type="table-fn"}^ (±3.31)                                      46.34^[a](#tb1fn1){ref-type="table-fn"},[b](#tb1fn2){ref-type="table-fn"}^ (±3.53)                                      43.52^[b](#tb1fn2){ref-type="table-fn"},[c](#tb1fn3){ref-type="table-fn"}^ (±6.33)
                                  Non-dominant (/50)           50[^‡^](#tb1fn8){ref-type="table-fn"}                                                                                   48.17^[a](#tb1fn1){ref-type="table-fn"},[c](#tb1fn3){ref-type="table-fn"}^ (±2.586)                                     46.27^[a](#tb1fn1){ref-type="table-fn"}^ (±5.05)                                                                        43.77^[c](#tb1fn3){ref-type="table-fn"}^ (±6.55)
  GRASSP-M sensation              Dominant (/12)               12[^‡^](#tb1fn8){ref-type="table-fn"}                                                                                   10.73^[c](#tb1fn3){ref-type="table-fn"}^ (±1.87)                                                                        10.69^[b](#tb1fn2){ref-type="table-fn"}^ (±1.47)                                                                        8.56^[b](#tb1fn2){ref-type="table-fn"},[c](#tb1fn3){ref-type="table-fn"}^ (±3.26)
                                  Non-dominant (/12)           12[^‡^](#tb1fn8){ref-type="table-fn"}                                                                                   11.03^[c](#tb1fn3){ref-type="table-fn"}^ (±1.65)                                                                        10.85^[b](#tb1fn2){ref-type="table-fn"}^ (±1.49)                                                                        8.34^[b](#tb1fn2){ref-type="table-fn"},[c](#tb1fn3){ref-type="table-fn"}^ (±3.28)
  GRASSP-M prehension/dexterity   Dominant (/9)                8.57^[d](#tb1fn4){ref-type="table-fn"},[e](#tb1fn5){ref-type="table-fn"},[f](#tb1fn6){ref-type="table-fn"}^ (±0.676)    7.05^[a](#tb1fn1){ref-type="table-fn"},[c](#tb1fn3){ref-type="table-fn"},[d](#tb1fn4){ref-type="table-fn"}^ (±1.22)     5.95^[a](#tb1fn1){ref-type="table-fn"},[b](#tb1fn2){ref-type="table-fn"},[e](#tb1fn5){ref-type="table-fn"}^ (±1.55)     4.66^[b](#tb1fn2){ref-type="table-fn"},[c](#tb1fn3){ref-type="table-fn"},[f](#tb1fn6){ref-type="table-fn"}^ (±2.03)
                                  Dominant time (sec)          47.05 (±22.41)                                                                                                          52.71^[a](#tb1fn1){ref-type="table-fn"},[c](#tb1fn3){ref-type="table-fn"}^ (±18.17)                                     66.93^[a](#tb1fn1){ref-type="table-fn"}^ (±25.39)                                                                       84.06^[c](#tb1fn3){ref-type="table-fn"}^ (±45.53)
                                  Non-dominant (/9)            8.62^[d](#tb1fn4){ref-type="table-fn"},[e](#tb1fn5){ref-type="table-fn"},[f](#tb1fn6){ref-type="table-fn"}^ (±0.669)    6.58^[a](#tb1fn1){ref-type="table-fn"},[c](#tb1fn3){ref-type="table-fn"},[d](#tb1fn4){ref-type="table-fn"}^ (±1.31)     5.54^[a](#tb1fn1){ref-type="table-fn"},[b](#tb1fn2){ref-type="table-fn"},[e](#tb1fn5){ref-type="table-fn"}^ (±1.55)     4.23^[b](#tb1fn2){ref-type="table-fn"},[c](#tb1fn3){ref-type="table-fn"},[f](#tb1fn6){ref-type="table-fn"}^ (±1.82)
                                  Non-dominant time (sec)      50.52^[d](#tb1fn4){ref-type="table-fn"},[e](#tb1fn5){ref-type="table-fn"},[f](#tb1fn6){ref-type="table-fn"}^ (±14.97)   60.21^[a](#tb1fn1){ref-type="table-fn"},[c](#tb1fn3){ref-type="table-fn"},[d](#tb1fn4){ref-type="table-fn"}^ (±18.91)   72.61^[a](#tb1fn1){ref-type="table-fn"},[b](#tb1fn2){ref-type="table-fn"},[e](#tb1fn5){ref-type="table-fn"}^ (±23.18)   94.13^[b](#tb1fn2){ref-type="table-fn"},[c](#tb1fn3){ref-type="table-fn"},[f](#tb1fn6){ref-type="table-fn"}^ (±44.73)

^a^Indicates statistical significance between mild and moderate groups (*P* ≤ .05).

^b^Indicates statistical significance between moderate and severe groups (*P* ≤ .05).

^c^Indicates statistical significance between mild and severe groups (*P* ≤ .05).

^d^Indicates statistical significance between control and mild groups (*P* ≤ .05).

^e^Indicates statistical significance between control and moderate groups (*P* ≤ .05).

^f^Indicates statistical significance between control and severe groups (*P* ≤ .05).

^†^Indicates normative value taken from the literature^[@bib21]^.

^‡^Indicates values expected of healthy controls.

In a sub-analysis of mild DCM patients, the opponens pollicis, abductor digiti minimi, first dorsal interossi, and anterior deltoid muscles consistently demonstrated mild weakness (grade 3 and 4) (*P* = 1.69 E-07).

Imaging {#sec3-3}
-------

All study participants did have a conventional MRI, and we used signal change and number of levels to describe the sample. In all, 41% to 48% of each severity group presented with T2 weighted signal change, (48%-mild, 41%-moderate, and 46%-severe). In all, 3% to 8% of each severity group presented with T1 weighted signal change, (5%-mild, 3%-moderate, and 8%-severe). In all, 5% to 17% of each severity group presented with both T1 and T2 weighted signal change, (5%-mild, 10%-moderate, and 17%-severe). Within each severity group, 29% to 42% of the sample had no signal change (42%-mild, 46%-moderate, and 29%-severe). There is not a large difference between the mild and moderate groups, whereas severe patients clearly have greater prevalence of signal change. There was an increase in the number of levels compressed as patients became more severe. The prevalence of 1 to 2 level compression for each severity group ranged from 62% to 30% (62%-mild, 54%-moderate, and 30%-severe), 3 levels of compression for each severity group ranged between 11% and 26% (18%-mild, 26%-moderate, and 11%-severe), and 4 to 5 levels of compression ranged from 19% to 37% (19%-mild, 20%-moderate, and 37%-severe). Again, the number of levels compressed was found to have some relationship to severity and some discriminative qualities. In this report of imaging, 22% to 29% of the imaging was not available for the signal change summary; however, it was complete for the number of levels compressed summary.

Reliability {#sec3-4}
-----------

Table [2](#tbl2){ref-type="table"} reports the ICC and CI for inter-rater (n = 31) and intra-rater reliabilities (n = 44). The ICC for inter-rater reliability was 0.869 (95% CI: 0.759-0.928) in the dominant hand and 0.862 (95% CI: 0.748-0.925) in the non-dominant hand. The ICC for intra-rater reliability was 0.868 (95% CI: 0.727-0.936) in the dominant hand and 0.790 (95% CI: 0.565-0.899) in the non-dominant hand.

###### 

Inter- and Intra-rater Reliability for GRASSP-M Prehension/Dexterity Subtest

                      Inter-rater reliability                   Intra-rater reliability                                             
  ------------------- ----------------------------------------- ------------------------- ----------------------------------------- -------------
  Dominant hand       0.869[\*](#tb2fn1){ref-type="table-fn"}   0.759-0.928               0.868[\*](#tb2fn1){ref-type="table-fn"}   0.727-0.936
  Non-dominant hand   0.862[\*](#tb2fn1){ref-type="table-fn"}   0.748-0.925               0.790[\*](#tb2fn1){ref-type="table-fn"}   0.565-0.899

\*Indicates statistical significance (*P* ≤ .05).

Validity {#sec3-5}
--------

Table [3](#tbl3){ref-type="table"} shows the Pearson correlation coefficients between baseline GRASSP-M and mJOA. All GRASSP-M subtests showed a positive, moderate correlation with the upper limb motor, upper limb sensory, and total upper limb mJOA scores. Dexterity time showed a negative, moderate correlation with these scores. All correlations were significant except for the correlation between dexterity time in the dominant hand and the mJOA upper limb sensation score. Known groups' validity is illustrated in Table [4](#tbl4){ref-type="table"}. The prehension/dexterity score was the most discriminative subtest of the GRASSP-M, followed by the strength subscore. Finally, Table [5](#tbl5){ref-type="table"} defines the thresholds set for each severity specific to the hand with the GRASSP-M.

###### 

Concurrent Validity

  Subtest                              UL mJOA        UL motor mJOA                              Sensation mJOA                             
  ------------------------------------ -------------- ------------------------------------------ ------------------------------------------ ------------------------------------------
  GRASSP-M strength                    Dominant       0.431[\*](#tb3fn1){ref-type="table-fn"}    0.373[\*](#tb3fn1){ref-type="table-fn"}    0.323[\*](#tb3fn1){ref-type="table-fn"}
                                       Non-dominant   0.406[\*](#tb3fn1){ref-type="table-fn"}    0.384[\*](#tb3fn1){ref-type="table-fn"}    0.251[\*](#tb3fn1){ref-type="table-fn"}
  GRASSP-M sensation                   Dominant       0.412[\*](#tb3fn1){ref-type="table-fn"}    0.374[\*](#tb3fn1){ref-type="table-fn"}    0.280[\*](#tb3fn1){ref-type="table-fn"}
                                       Non-dominant   0.488[\*](#tb3fn1){ref-type="table-fn"}    0.448[\*](#tb3fn1){ref-type="table-fn"}    0.323[\*](#tb3fn1){ref-type="table-fn"}
  GRASSP-M prehension/dexterity        Dominant       0.502[\*](#tb3fn1){ref-type="table-fn"}    0.511[\*](#tb3fn1){ref-type="table-fn"}    0.250[\*](#tb3fn1){ref-type="table-fn"}
                                       Non-dominant   0.533[\*](#tb3fn1){ref-type="table-fn"}    0.524[\*](#tb3fn1){ref-type="table-fn"}    0.301[\*](#tb3fn1){ref-type="table-fn"}
  GRASSP-M prehension/dexterity time   Dominant       −0.407[\*](#tb3fn1){ref-type="table-fn"}   −0.455[\*](#tb3fn1){ref-type="table-fn"}   −0.138
                                       Non-dominant   −0.439[\*](#tb3fn1){ref-type="table-fn"}   −0.469[\*](#tb3fn1){ref-type="table-fn"}   −0.186[\*](#tb3fn1){ref-type="table-fn"}

\*Indicates statistical significance (*P* ≤ .05).

###### 

Discriminative Qualities of GRASSP-M Domains

                                       *P*-value                      
  ------------------------------------ -------------- ------- ------- -------
  GRASSP-M strength                    Dominant       0.019   0.028   0.001
                                       Non-dominant   0.028   0.079   0.001
  GRASSP-M sensation                   Dominant       0.883   0.001   0.001
                                       Non-dominant   0.567   0.000   0.000
  GRASSP-M prehension/dexterity        Dominant       0.000   0.004   0.000
                                       Non-dominant   0.001   0.002   0.000
  GRASSP-M prehension/dexterity time   Dominant       0.002   0.062   0.001
                                       Non-dominant   0.005   0.019   0.000

(*P* ≤ .016) refers to a significant difference between groups and the *P*-value reflects a Bonferroni Correction.

###### 

GRASSP-M Discriminative Values for Assessment of DCM

  GRASSP-M             Control   Mild                       Moderate   Severe
  -------------------- --------- -------------------------- ---------- --------------
  GRASSP-Str (0-50)    50        48-46 note which muscles   45-40      Less than 40
  GRASSP-Sens (0-12)   11-12     10                         9-8        Less than 8
  GRASSP-PD (0-9)      8-9       8-7                        6-5        Less than 5

DISCUSSION {#sec4}
==========

Although impairment of manual dexterity and weakness of intrinsic hand muscles are some of the earliest symptoms of DCM,^[@bib4],[@bib8]^ upper limb dysfunction has not been adequately characterized. This study aims to fill this knowledge gap by developing an assessment tool to quantify impairment in hand function. It is crucial to understand patients' upper limb deficits at the time of diagnosis to appropriately determine their clinical plan.^[@bib11]^ Proper patient management requires using gold standard measures, such as the mJOA, and objective, sensitive clinical tools to define the different DCM severities. We have presented the characteristics of upper limb impairment and introduced a new upper limb tool to the DCM field. We conclude that there are elements of dysfunction that are currently not captured with standard DCM assessments, indicating clinical decisions have not always been based on patients' true deficits. For example, the traditional myotomal upper limb exam does not assess the intrinsic hand muscles,^[@bib24]^ which we have shown are impacted early in the disease process.

The majority of DCM patients in this study reported upper limb dysfunction, including those with mild DCM. This finding is consistent with previous studies, which reveal that upper limb numbness and impaired dexterity are experienced early in the disease process.^[@bib2],[@bib8],[@bib25],[@bib26]^ There was a significant difference in the prehension/dexterity subtest scores and time for completion between the patients' 2 hands; thus, the average grip dynamometry and GRASSP-M subtest scores for dominant and non-dominant hands were reported separately. We noted that strength (GRASSP-M strength), sensation, and dexterity decreased as severity increased, which is consistent with the literature.^[@bib26]^ However, grip strength did not significantly decrease as severity increased in our sample. We emphasize the importance of an objective clinical tool that can quantify all aspects of upper limb impairment, such as the GRASSP-M, in guiding clinical decision-making.

Reliability and Validity {#sec4-1}
------------------------

Inter- and intra-rater reliabilities for all GRASSP-M subtests were high and above our predefined threshold of 0.75. These results indicate that the GRASSP-M is a reliable tool.

Concurrent validity was evaluated by assessing the correlation between the GRASSP-M subsets and the mJOA upper extremity subscores. The GRASSP-M measures subtle changes in hand function that may not be fully captured by the mJOA. As a result, we did not expect a strong correlation between all GRASSP-M subtests and the mJOA subscores. Based on our results, the majority of GRASSP-M subtests were moderately and significantly correlated with the mJOA upper extremity subscores. The exception to this was the correlation between dexterity time and mJOA sensation score, which did not reach statistical significance. These results demonstrate concurrent validity and indicate that the GRASSP-M captures aspects of hand function that the mJOA may not. Furthermore, the GRASSP-M strength and sensation subtests, as well as the time required to complete the prehension/dexterity subtest, were able to discriminate among patients with mild, moderate, and severe DCM. These results support the use of the GRASSP-M as an adjuvant tool for the assessment of dexterity function and disease progression.

GRASSP-M {#sec4-2}
--------

Through this study we characterized hand impairment in DCM and also set discriminative thresholds related to impairment. The initial step was to define discriminative qualities of the new measures in relation to the mild, moderate, and severe sub-groupings defined by the mJOA. The mean was used as the primary value to define the thresholds for mild, moderate, and severe (Table [1](#tbl1){ref-type="table"}). The thresholds in Table [5](#tbl5){ref-type="table"} can be used to define severity specific to the hand and upper limb. The dexterity score is the most useful subtest; it can be used to confirm the mJOA severity or determine if there is more loss of function specific to the hand than a mild patient should present with.

Insights Into Mild DCM {#sec4-3}
----------------------

The opponens pollicis, abductor digiti minimi, first dorsal interossei, and anterior deltoid muscles demonstrated significant weakness early in the disease process. These findings are not surprising, as weakness of the intrinsic hand muscles is one of the first symptoms of DCM.^[@bib14],[@bib15]^ Furthermore, the anterior deltoid muscle often activates during movement of intrinsic hand muscles^[@bib29],[@bib30]^; as a result, concomitant impairment of the anterior deltoid and intrinsic hand muscles was observed. These results suggest that assessing intrinsic hand muscles is as important as evaluating the larger muscle groups, especially in patients with mild DCM. Therefore, in addition to the traditional C5-T1 myotomal testing, these 4 muscles should be tested to elucidate the level of impairment in patients with mild DCM.

This study also demonstrated that a proportion of patients classified as mild on the mJOA in fact have moderate impairment of dexterity. With the GRASSP-M, patients with moderate DCM scored, on average, a 5.95/9 and 5.54/9 on their dominant and non-dominant hands, respectively. As such, a score ≤5 is likely representative of moderate dexterity impairment. In the mild cohort, 28% of patients scored a ≤5/9 on the prehension/dexterity subtest with at least 1 hand; these mild patients actually presented with moderately impaired dexterity. Recent guidelines have recommended surgical treatment for mild DCM patients with progressive myelopathy to prevent further neurologic deterioration and optimize outcomes.^[@bib10]^ Given these guidelines, it is important to differentiate between patients who are likely to progress and those who may benefit from a trial of nonoperative therapy. Patients who present with a greater degree of functional impairment are likely at a higher risk of neurological decline and may be candidates for surgery.^[@bib31]^ Assessment using the GRASSP-M could help to determine which mild patients have moderate levels of functional hand impairment and should be counseled for surgical intervention.

Limitations {#sec4-4}
-----------

We excluded patients with focal neurological comorbidities such as stroke, multiple sclerosis, rheumatoid arthritis, brachial plexus injury, and peripheral neuropathies, as these comorbidities may cause similar deficits as DCM. However, we did not exclude patients with diabetes, hypertension, and osteoarthritis; these diseases may impact a patient\'s total mJOA score. However, by excluding individuals with pathologies affecting the upper limbs, we reduced the impact or influence of any other disease on this sample. Another limitation is that although a control sample was recruited and tested, some comparative variables were defined by the existing medical literature. In particular, grip strength for the sample was compared to normative values defined in the medical literature. Published normative values are typically based on a sample specifically collected to reflect normal values, and we felt our control sample was not superior to this study. With respect to GRASSP domains of strength and sensation, we compare the impaired group to expected normal values, which is represented by the highest score. The GRASSP is designed to score with respect to normal, which is the maximum score on each scale.^[@bib18]^

It is also important to note that hand dysfunction and upper extremity deficits are only one aspect of the impairments that individuals with DCM present with. Gait deficits also play a significant role in their global disability, and while we do not report on gait in this paper, many of the mild DCM study participants and all of the moderate and severe individuals did present with some gait impairment. The gait impairment findings will be reported in a separate study. Finally, it is important to mention that this study was conducted at a single center, which may introduce selection bias.

CONCLUSION {#sec5}
==========

The GRASSP-M can objectively quantify hand impairment and can assess DCM severity more accurately than the widely used subjective measures. This information allows for earlier diagnosis of DCM, improved patient monitoring, and treatment planning. This study has demonstrated that the GRASSP-M is a valid and reliable tool for quantifying fine motor skill dysfunction in a clinical setting. As a result, we recommend that clinicians use the GRASSP-M to assess and monitor patients with DCM, regardless of whether they are candidates for surgery. The GRASSP-M can be administered by any clinician with good assessment skills, and the test can be performed in 10 to 15 min, providing useful diagnostic information for the clinical team. Unification of outcome assessment will allow the field to accurately quantify the progression of DCM and prognosticate treatment outcomes.
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